SK

Savita Kumari

Active Director Director DIN 09403170
DIN 09403170 First appointment Nov 2021 Primary industry Healthcare
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Nov 2021
Shareholding value •••• Premium profile

About Savita Kumari

Data last updated:

Savita Kumari is a Director at Aro Pharma Private Limited (since 2021). The company operates in Healthcare. Aro Pharma Private Limited reported revenue of ₹5 Lakh (FY 2025).

DIN 09403170
Primary Designation Director
Industry Healthcare
First Appointment 17 Nov 2021
Oldest Company Age 4 yrs
Largest company Aro Pharma Private Limited · ₹5 Lakh (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Aro Pharma Private Limited U85100BR2021PTC055180
Director17 Nov 20212021₹5 Lakh (FY 2025)Active

Board colleagues of Savita Kumari

NameDINCompanyDesignation
Upendra Nath Thakur09403169Aro Pharma Private LimitedDirector

Directorship timeline

Open interactive timeline →
Aro Pharma Private Limited
Premium access

Shareholding and investment profile for Savita Kumari

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Savita Kumari

Savita Kumari currently holds 1 directorship: Aro Pharma Private Limited (Director, since 17 Nov 2021, revenue ₹5 Lakh (FY 2025)).

Savita Kumari was first appointed on 17 Nov 2021 as Director at Aro Pharma Private Limited.

The current boards of Savita Kumari's companies include Upendra Nath Thakur (Aro Pharma Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available